Business Description
RAPT Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US75382E1091
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 22.39 | |||||
Equity-to-Asset | 0.84 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -0.05 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -15 | |||||
3-Year EPS without NRI Growth Rate | -11.7 | |||||
3-Year FCF Growth Rate | -14.8 | |||||
3-Year Book Growth Rate | 0.5 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 5.3 | |||||
9-Day RSI | 11.79 | |||||
14-Day RSI | 18.46 | |||||
6-1 Month Momentum % | -38.58 | |||||
12-1 Month Momentum % | -55.68 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 7.01 | |||||
Quick Ratio | 7.01 | |||||
Cash Ratio | 6.69 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11.6 | |||||
Shareholder Yield % | -5.12 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -67.78 | |||||
ROA % | -59.15 | |||||
ROIC % | -682.07 | |||||
ROC (Joel Greenblatt) % | -1536.68 | |||||
ROCE % | -71.43 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.16 | |||||
Price-to-Tangible-Book | 1.16 | |||||
EV-to-EBIT | -0.12 | |||||
EV-to-Forward-EBIT | -0.12 | |||||
EV-to-EBITDA | -0.13 | |||||
EV-to-Forward-EBITDA | -0.12 | |||||
EV-to-Forward-Revenue | 242.61 | |||||
EV-to-FCF | -0.15 | |||||
Price-to-Net-Current-Asset-Value | 1.23 | |||||
Price-to-Net-Cash | 1.3 | |||||
Earnings Yield (Greenblatt) % | -833.33 | |||||
FCF Yield % | -70.14 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
RAPT Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -2.847 | ||
Beta | 0.53 | ||
Volatility % | 141.44 | ||
14-Day RSI | 18.46 | ||
14-Day ATR (€) | 0.47703 | ||
20-Day SMA (€) | 7.2805 | ||
12-1 Month Momentum % | -55.68 | ||
52-Week Range (€) | 4.14 - 24.2 | ||
Shares Outstanding (Mil) | 34.9 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
RAPT Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
RAPT Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
RAPT Therapeutics Inc Frequently Asked Questions
What is RAPT Therapeutics Inc(FRA:0RA)'s stock price today?
When is next earnings date of RAPT Therapeutics Inc(FRA:0RA)?
Does RAPT Therapeutics Inc(FRA:0RA) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |